INTERVIEW: MAP Diagnostics pushes urine-based noninvasive prenatal Down syndrome test
This article was originally published in Clinica
For a long time, screening for Down syndrome during pregnancy has left a lot to be desired. The current standard of care involves several blood tests and an ultrasound scan – women whose pregnancies are deemed to be at-risk are then referred for invasive amniocentesis, which comes with a chance of miscarriage.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.